Carlotta Antoniotti
University of Pisa
159 Papers
244 Citations
Carlotta Antoniotti is an academic researcher from University of Pisa. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 22, co-authored 116 publications. Previous affiliations of Carlotta Antoniotti include University of Turin & University of Würzburg.
Chat about Author
Papers
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna,Benedetta Mussolin,Michela Buscarino,Giorgio Corti,Andrea Cassingena,Giovanni Crisafulli,Agostino Ponzetti,Chiara Cremolini,Alessio Amatu,Calogero Lauricella,Simona Lamba,Sebastijan Hobor,Antonio Avallone,Emanuele Valtorta,Giuseppe Rospo,Enzo Medico,Valentina Motta,Carlotta Antoniotti,Fabiana Tatangelo,Beatriz Bellosillo,Silvio Veronese,Alfredo Budillon,Clara Montagut,Patrizia Racca,Silvia Marsoni,Alfredo Falcone,Ryan B. Corcoran,Federica Di Nicolantonio,Fotios Loupakis,Salvatore Siena,Andrea Sartore-Bianchi,Alberto Bardelli +31 more
TL;DR: The results indicate that the CRC genome adapts dynamically to intermittent drug schedules and provide a molecular explanation for the efficacy of rechallenge therapies based on EGFR blockade.
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini,Fotios Loupakis,Carlotta Antoniotti,Cristiana Lupi,Elisa Sensi,Sara Lonardi,Silvia Mezi,Gianluca Tomasello,Monica Ronzoni,Alberto Zaniboni,Giuseppe Tonini,Chiara Carlomagno,Giacomo Allegrini,Silvana Chiara,Mauro D'Amico,Cristina Granetto,Marina Cazzaniga,Luca Boni,Gabriella Fontanini,Alfredo Falcone +19 more
TL;DR: An updated analysis of the TRIBE study aimed to provide mature results for overall survival-a secondary endpoint-and report treatment efficacy in RAS and BRAF molecular subgroups, and assessed the secondary endpoint of overall survival in the main cohort.
1K
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Filippo Pietrantonio,Federica Di Nicolantonio,Alexa B. Schrock,Jeeyun Lee,Sabine Tejpar,Andrea Sartore-Bianchi,Jaclyn F. Hechtman,Jason Christiansen,Luca Novara,Niall C. Tebbutt,Giovanni Fucà,Carlotta Antoniotti,Seung Tae Kim,Danielle Murphy,Rosa Berenato,Federica Morano,James Sun,Bosun Min,Philip J. Stephens,Marissa Chen,Luca Lazzari,Vincent A. Miller,Robert H. Shoemaker,Alessio Amatu,Massimo Milione,Jeffrey S. Ross,Salvatore Siena,Alberto Bardelli,Siraj M. Ali,A. Falcone,Filippo de Braud,Chiara Cremolini +31 more
TL;DR: ALK, ROS1, and NTRK rearrangements define a new rare subtype of mCRC with extremely poor prognosis, and four evaluable patients with rearranged patients showed primary resistance to anti-epidermal growth factor receptor agents.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini,Carlotta Antoniotti,Daniele Rossini,Sara Lonardi,Fotios Loupakis,Filippo Pietrantonio,Roberto Bordonaro,Tiziana Latiano,Emiliano Tamburini,Daniele Santini,Alessandro Passardi,Federica Marmorino,Roberta Grande,Giuseppe Aprile,Alberto Zaniboni,Sabina Murgioni,Cristina Granetto,Angela Buonadonna,Roberto Moretto,Salvatore Corallo,Stefano Cordio,Lorenzo Antonuzzo,Gianluca Tomasello,Gianluca Masi,Monica Ronzoni,Samantha Di Donato,Chiara Carlomagno,Matteo Clavarezza,Giuliana Ritorto,Andrea Mambrini,Mario Roselli,Samanta Cupini,Serafina Mammoliti,Elisabetta Fenocchio,Enrichetta Corgna,Vittorina Zagonel,Gabriella Fontanini,Clara Ugolini,Luca Boni,Alfredo Falcone,Filippo de Braud,Evaristo Maiello,Giovanni Luca Frassineti,Teresa Gamucci,Francesco Di Costanzo,Luca Gianni,Patrizia Racca,Giacomo Allegrini,Alberto Sobrero,Massimo Aglietta,Enrico Cortesi,Domenico Corsi,Alberto Ballestrero,Andrea Bonetti,Francesco Di Clemente,Enzo Maria Ruggeri,Fortunato Ciardiello,Marco Benasso,Stefano Vitello,Saverio Cinieri,Stefania Mosconi,Nicola Silvestris,Antonio Frassoldati,Samantha Cupini,Alessandro Bertolini,Giampaolo Tortora,Carmelo Bengala,Daris Ferrari,Antonia Ardizzoia,Carlo Milandri,Silvana Chiara,Gianpiero Romano,Stefania Miraglia,Laura Scaltriti,Francesca Pucci,Livio Blasi,Silvia Brugnatelli,Luisa Fioretto,A.S. Ribecco,Raffaella Longarini,Michela Frisinghelli,Maria Banzi +81 more
TL;DR: The triplet FOLFOXIRI showed improved outcomes for patients with metastatic colorectal cancer, compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab, but the actual benefit of the upfront exposure to the three cytotoxic drugs compared with a preplanned sequential strategy of doublets was not clear.
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Giovanni Fucà,Vincenzo Guarini,Carlotta Antoniotti,Federica Morano,Roberto Moretto,Salvatore Corallo,Federica Marmorino,Sara Lonardi,Lorenza Rimassa,Andrea Sartore-Bianchi,Beatrice Borelli,Marco Tampellini,Sara Bustreo,Matteo Claravezza,Alessandra Boccaccino,Roberto Murialdo,Alberto Zaniboni,Gianluca Tomasello,Fotios Loupakis,Vincenzo Adamo,Giuseppe Tonini,Enrico Cortesi,Filippo de Braud,Chiara Cremolini,Filippo Pietrantonio +24 more
TL;DR: PIV is a strong predictor of survival outcomes with better performance than other well-known IIBs in patients with metastatic CRC treated with first-line therapy and should be prospectively validated to better stratify mCRC patients undergoing first- line therapy.
193